Home-Based Care for Hypertension in Rural South Africa.
Siedner MJ, Magula N, Mazibuko L, Sithole N, Castle A, Nxumalo S, Manyaapelo T, Abrahams-Gessel S, Gareta D, Orne-Gliemann J, Baisley K, Bachmann M, Gaziano TA
- DOI
- 10.1056/NEJMoa2509958
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/c3582ee4-045f-445a-8d18-4a69cfed00e3 is authoritative.
How this rating was calculated
- StatisticsImpossible or misreported statistic ×5−5★
- IntegrityIntegrity concern ×2−1★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- StatisticsPrinted percentage does not match its own count (capped) ×23−0.25★
- ReportingData & code availability partially met−0.25★
A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.
- The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 15 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
- No data or code availability links were detected to verify.
- 01Printed percentage does not match its own countdemonstrable
89% does not match the reported count 227/259
“227 (89.0%)”
Table 1 - 02Printed percentage does not match its own countdemonstrable
89% does not match the reported count 226/257
“226 (89.0%)”
Table 1 - 03Printed percentage does not match its own countdemonstrable
87.9% does not match the reported count 225/258
“225 (87.9%)”
Table 1 - 04Printed percentage does not match its own countdemonstrable
88.6% does not match the reported count 678/774
“678 (88.6%)”
Table 1 - 05Printed percentage does not match its own countdemonstrable
22.7% does not match the reported count 57/257
“57 (22.7%)”
Table 1 - 06Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy claim is based on systolic blood pressure (SBP) at 6 months, which is a surrogate endpoint for cardiovascular outcomes. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) nor does it cite validated evidence linking SBP reduction to clinical outcomes within the manuscript. Although the discussion mentions that an 8-10 mmHg reduction is associated with a 15-25% reduction in risk of heart attack, stroke, and heart failure, this is not a formal validation of the surrogate and is not presented as such.
“The primary outcome was systolic BP at 6 months.”
23 further findings of this severity or below — every one is in the sections below, filed under its error type.
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and well-reported randomized controlled trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weaknesses are the lack of an explicit data availability statement and code sharing, and minor reporting gaps (statistical software, CONSORT adherence, outlier handling).
Both reviewers classified the study as interventional and agreed on all dimension statuses. The statistics verification component could only recompute a subset of tests (4 of 32) due to threshold-only p-values and other non-verifiable formats; no errors were found in the checked subset. The citation check found no retracted or unresolved references.
Numerical inconsistencies
3 findings · worst criticalValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
- Printed percentage does not match its own countRecomputed
- Internal contradictions in the reported numbersAssessed
Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 5 reported summary statistics mathematically impossible for the stated N (PERCENT). 23 printed percentages that do not match their own count.
- PERCENT43% does not match the reported count 110/257
“110 (43.0%)”
Table 1 - PERCENT33.2% does not match the reported count 85/257
“85 (33.2%)”
Table 1 - PERCENT89% does not match the reported count 227/259
“227 (89.0%)”
Table 1 - PERCENT89% does not match the reported count 226/257
“226 (89.0%)”
Table 1 - PERCENT87.9% does not match the reported count 225/258
“225 (87.9%)”
Table 1 - PERCENT88.6% does not match the reported count 678/774
“678 (88.6%)”
Table 1 - PERCENT17.1% does not match the reported count 43/257
“43 (17.1%)”
Table 1 - PERCENT21.5% does not match the reported count 55/258
“55 (21.5%)”
Table 1 - PERCENT21.2% does not match the reported count 162/774
“162 (21.2%)”
Table 1 - PERCENT21.5% does not match the reported count 54/257
“54 (21.5%)”
Table 1 - PERCENT19.9% does not match the reported count 51/258
“51 (19.9%)”
Table 1 - PERCENT19.2% does not match the reported count 147/774
“147 (19.2%)”
Table 1 - PERCENT22.5% does not match the reported count 58/259
“58 (22.5%)”
Table 1 - PERCENT20.3% does not match the reported count 51/257
“51 (20.3%)”
Table 1 - PERCENT16.4% does not match the reported count 42/258
“42 (16.4%)”
Table 1 - PERCENT19.7% does not match the reported count 151/774
“151 (19.7%)”
Table 1 - PERCENT18.3% does not match the reported count 46/257
“46 (18.3%)”
Table 1 - PERCENT20.7% does not match the reported count 53/258
“53 (20.7%)”
Table 1 - PERCENT20% does not match the reported count 153/774
“153 (20.0%)”
Table 1 - PERCENT22.7% does not match the reported count 57/257
“57 (22.7%)”
Table 1 - PERCENT21.5% does not match the reported count 55/258
“55 (21.5%)”
Table 1 - PERCENT19.9% does not match the reported count 152/774
“152 (19.9%)”
Table 1 - PERCENT84.5% does not match the reported count 218/259
“218 (84.5%)”
Table 1 - PERCENT86.7% does not match the reported count 222/257
“222 (86.7%)”
Table 1 - PERCENT85.5% does not match the reported count 660/774
“660 (85.5%)”
Table 1 - PERCENT76.9% is unattainable for n=257 (nearest: 76.7, 77%)
“76.9% (71.2, 81.7)”
Table 2Find in source - PERCENT82.8% is unattainable for n=258 (nearest: 82.6, 82.9%)
“82.8% (77.7, 87.0)”
Table 2Find in source - PERCENT57.7% is unattainable for n=259 (nearest: 57.5, 57.9%)
“57.7% (51.5, 63.7)”
Table 2Find in source
- CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1Primary outcome: difference in mean systolic BP at 6 months, CHW vs SOC
“Compared to SOC, mean systolic BP at 6 months was lower in the CHW arm (−7.9mm Hg, 95%CI −10.5, −5.3, P<0.001)”
Taken as given: The estimate is the difference in means (-7.9) and the CI is a 95% confidence interval for that difference.; The p-value is two-sided for the null hypothesis that the difference is zero.Method: Recomputed two-sided p-value from the reported estimate and 95% CI using the normal approximation.How we recomputed it: pCI(-7.9, -10.5, -5.3, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1Primary outcome: difference in mean systolic BP at 6 months, eCHW+ vs SOC
“Compared to SOC, mean systolic BP at 6 months was lower in the CHW arm (−7.9mm Hg, 95%CI −10.5, −5.3, P<0.001) and eCHW+ arm (−9.1mmHg, 95%CI −11.7, −6.4, P<0.001).”
Taken as given: The estimate is the difference in means (-9.1) and the CI is a 95% confidence interval for that difference.; The p-value is two-sided for the null hypothesis that the difference is zero.Method: Recomputed two-sided p-value from the reported estimate and 95% CI using the normal approximation.How we recomputed it: pCI(-9.1, -11.7, -6.4, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2P-value for difference in systolic BP at 6 months between CHW and SOC arms
“difference vs SOC −7.9mmHg, 95%CI −10.5, −5.3, P-value<0.001”
Taken as given: The estimate is the mean difference in systolic BP.; The 95% CI is two-sided.; The p-value is two-tailed.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.How we recomputed it: pCI(-7.9, -10.5, -5.3, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2P-value for difference in systolic BP at 6 months between eCHW+ and SOC arms
“difference vs SOC −9.1mmHg, 95%CI −11.7, −6.4, P-value<0.001”
Taken as given: The estimate is the mean difference in systolic BP.; The 95% CI is two-sided.; The p-value is two-tailed.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation.How we recomputed it: pCI(-9.1, -11.7, -6.4, 0)
- lowinternal contradictionThe abstract reports 774 randomized, but the results section states 762 completed the 6-month follow-up and were included in the primary ITT analysis. This is expected due to loss to follow-up, but the abstract does not mention the 12 missing.
Abstract: 'We randomized 774 individuals.' ; Results: 'Of these 762 (98%) completed the 6-month follow-up visit and were included in the primary intention-to-treat analysis.'
Abstractreviewer’s wording - lowinternal contradictionThe abstract reports hypertension control at 6 months as 76.9% in the CHW arm, while the results section reports 76.8% in the same arm.
Abstract: 'hypertension control at 6 months was 57.6%, compared to 76.9% in the CHW arm' ; Results: 'The proportion of participants achieving hypertension control based on South African Department of Health definitions at 6 months was 57.6% in the SOC arm (95%CI 51.5, 63.6), 76.8% in the CHW arm (95%CI 71.2, 81.7)'
Abstractreviewer’s wording
Overstated conclusions
1 finding · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
5 major claims checked against the paper's own evidence: all adequately supported.
- supportedReviewers 1, 2Home-based hypertension care led to significant reductions in systolic BP and improvements in hypertension control in South Africa.The primary outcome (systolic BP at 6 months) and secondary outcome (hypertension control) both show statistically significant improvements in the intervention arms compared to SOC, with effect sizes and CIs reported.Evidence: Abstract reports mean systolic BP lower by 7.9 and 9.1 mmHg in CHW and eCHW+ arms, with P<0.001; hypertension control higher (76.9% and 82.8% vs 57.6%).
“Home-based hypertension care led to significant reductions in systolic BP and improvements in hypertension control in South Africa.”
ConclusionFind in source - supportedReviewers 1, 2Improved BP with home-based care appeared to persist at 12 months.The 12-month data show sustained reductions in systolic BP and higher control rates in intervention arms, though the primary outcome was at 6 months.Evidence: Table 2 shows 12-month systolic BP differences of -10.3 and -10.5 mmHg vs SOC, and control rates of 82.8% and 85.7% vs 57.7%.
“Improved BP with home-based care appeared to persist at 12 months.”
AbstractFind in source - supportedReviewers 1, 2Severe adverse events and deaths were uncommon and similar across arms.The reported rates of severe adverse events (2.7% overall) and deaths (1.0% overall) are low and appear similar across arms, with no study-related events.Evidence: Table 2 shows severe adverse events: SOC 4 (1.6%), CHW 7 (2.7%), eCHW+ 10 (3.9%); deaths: 3 (1.2%), 1 (0.4%), 4 (1.6%).
“Severe adverse events (2.7%) and deaths (1.0%) were uncommon and similar across arms.”
AbstractFind in source - supportedReviewers 1, 2Retention in care remained >95% in both intervention arms.Retention at 6 and 12 months is reported as >95% in both intervention arms, with CIs.Evidence: Table 2 shows retention at 6 months: CHW 98.1%, eCHW+ 99.6%; at 12 months: 97.3% and 97.7%.
“Retention in care remained >95% in both intervention arms.”
AbstractFind in source - supportedReviewers 1, 2The 8–10mmHg reduction in mean systolic BP observed in the intervention arms has been associated with a 15–25% reduction in risk of heart attack, stroke, and heart failure.This claim is supported by prior literature, as cited in the discussion, and is presented as an association, not a direct result of this trial.Evidence: Discussion cites prior studies linking BP reduction to cardiovascular risk reduction.
“The 8–10mmHg reduction in mean systolic BP observed in the intervention arms has been associated with a 15–25% reduction in risk of heart attack, stroke, and heart failure.”
Discussion ¶1Find in source
Premise concern: surrogate not validated for clinical benefit.
- INADEQUATESurrogate endpointThe primary efficacy claim is based on systolic blood pressure (SBP) at 6 months, which is a surrogate endpoint for cardiovascular outcomes. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD or dose-exposure relationship) nor does it cite validated evidence linking SBP reduction to clinical outcomes within the manuscript. Although the discussion mentions that an 8-10 mmHg reduction is associated with a 15-25% reduction in risk of heart attack, stroke, and heart failure, this is not a formal validation of the surrogate and is not presented as such.
“The primary outcome was systolic BP at 6 months.”
- ADEQUATEEffect sizeThe reported effect sizes are clinically meaningful: a reduction in systolic BP of 7.9 mmHg (CHW) and 9.1 mmHg (eCHW+) compared to SOC, with 95% CIs excluding zero. The paper explicitly anchors these reductions to clinical benefit by stating that an 8-10 mmHg reduction is associated with a 15-25% reduction in risk of heart attack, stroke, and heart failure. The effect sizes are statistically supported and exceed the minimal clinically important difference for blood pressure.
“The 8–10mmHg reduction in mean systolic BP observed in the intervention arms has been associated with a 15–25% reduction in risk of heart attack, stroke, and heart failure.”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The background cites the global burden of hypertension and poor control rates, and identifies specific barriers in South Africa. It references prior studies and meta-analyses in the discussion, acknowledging gaps such as lack of combined strategies. The rationale linking home-based care to addressing structural barriers is clear.
“Elevated blood pressure (BP) is the leading risk factor for preventable mortality, responsible for approximately 10 million deaths each year.”
“Home-based BP management with remote monitoring has been proposed to address these barriers, but data on the efficacy of such programs are scarce.”
“Our study was unique among this body of research as the only one evaluating a home-based intervention in which participants received BP monitoring and visitation by lay healthcare workers.”
“Elevated blood pressure (BP) is the leading risk factor for preventable mortality, responsible for approximately 10 million deaths each year.”
“Home-based BP management with remote monitoring has been proposed to address these barriers, but data on the efficacy of such programs are scarce.”
Randomization method (REDCap, blocks of nine, stratified by clinic and treatment use) is described. Blinding of outcome assessors is stated. Power analysis is provided with assumptions. Inclusion/exclusion criteria are detailed. The analysis population (ITT) and missing data approach are defined. Controls are inherent in the SOC arm. Independent replication is not applicable for a single trial.
“Those eligible who provided informed consent were randomized 1:1:1 in blocks of nine to one of the three trial arms using the randomization module in REDCap.”
“Study staff not involved with the intervention program and blinded to study arm conducted home visits at 6 and 12 months after enrollment in all three arms to collect outcome data.”
“With a target enrollment of 774 participants (258 per arm), we had >80% power to detect a 5 mmHg difference between arms in mean systolic BP at 6 months, allowing for 20% loss to follow-up, a correlation between baseline and follow-up measurements of 0.5, and a two-tailed alpha of 2.5% to account for multiple comparisons between the SOC and both intervention arms.”
“Those eligible who provided informed consent were randomized 1:1:1 in blocks of nine to one of the three trial arms using the randomization module in REDCap.”
“Study staff not involved with the intervention program and blinded to study arm conducted home visits at 6 and 12 months after enrollment in all three arms to collect outcome data.”
“With a target enrollment of 774 participants (258 per arm), we had >80% power to detect a 5 mmHg difference between arms in mean systolic BP at 6 months, allowing for 20% loss to follow-up, a correlation between baseline and follow-up measurements of 0.5, and a two-tailed alpha of 2.5% to account for multiple comparisons between the SOC and both intervention arms.”
Sex is reported (76% women). Age, health status (diabetes, HIV, BMI, GFR) are reported. Demographics include education, employment, water access, and travel time. Since both sexes are enrolled, sex_justified is not applicable. Species/strain and housing are not applicable for a human trial.
“At enrollment, the mean age was 62 years (SD 12) and 76% (588/774) were women.”
“Forty-seven percent of participants (360/774) were living with HIV; whereas 14% (105/774) had diabetes and 45% (351/774) had a body mass index >30 kilogram/meter 2 .”
“At enrollment, the mean age was 62 years (SD 12) and 76% (588/774) were women.”
“Forty-seven percent of participants (360/774) were living with HIV; whereas 14% (105/774) had diabetes and 45% (351/774) had a body mass index >30 kilogram/meter 2 .”
The trial was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee, the IRB of Mass General Brigham, and the South African Health Products Regulatory Authority. All participants provided signed informed consent. Regulatory compliance is implied by these approvals.
“The trial was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee, the Institutional Review Board of Mass General Brigham and by the South African Health Products Regulatory Authority.”
“All participants provided signed informed consent.”
“The trial was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee, the Institutional Review Board of Mass General Brigham and by the South African Health Products Regulatory Authority.”
“All participants provided signed informed consent.”
The BP machines (Omron Digital M3, BlipCare) and the mobile application (iMarketing Consultants) are named with manufacturers. The application is described in detail. No antibodies, cell lines, or other bench reagents are used, so those are not applicable.
“In the CHW arm, participants received an automated BP machine (Omron Digital M3. Kyoto, Japan)”
“CHWs visited participants within one week of enrollment and approximately monthly thereafter to record BP readings into a mobile health application on their phones (iMarketing Consultants, Windhoek, Namibia”
“In the CHW arm, participants received an automated BP machine (Omron Digital M3. Kyoto, Japan)”
“CHWs visited participants within one week of enrollment and approximately monthly thereafter to record BP readings into a mobile health application on their phones (iMarketing Consultants, Windhoek, Namibia”
Tests are named (linear regression, logistic regression with marginal standardization). Assumptions are handled by design (pre-specified models). Exact p-values are reported for primary outcomes. Effect sizes with 95% CIs are reported throughout. Software is not explicitly named but is implied (REDCap, likely Stata/R). Data presentation includes CIs and per-group n. Mathematical plausibility checks were not possible for all values, but no obvious errors were found.
“For the primary outcome, we fit linear regression models to estimate the difference between arms in mean systolic BP at 6 months.”
“Compared to SOC, mean systolic BP at 6 months was lower in the CHW arm (−7.9mm Hg, 95%CI −10.5, −5.3, P<0.001) and eCHW+ arm (−9.1mmHg, 95%CI −11.7, −6.4, P<0.001).”
“Difference between arms at 6 months vs SOC | Reference | −7.9 (−10.5, −5.3) | −9.1 (−11.7, −6.4)”
“For the primary outcome, we fit linear regression models to estimate the difference between arms in mean systolic BP at 6 months.”
“difference vs SOC −7.9mmHg, 95%CI −10.5, −5.3, P-value<0.001”
“Difference between arms at 6 months vs SOC | Reference | −7.9 (−10.5, −5.3) | −9.1 (−11.7, −6.4)”
The paper mentions 'supp app' and 'Supplementary Material' but does not provide a clear data availability statement with a repository or access mechanism. No code is shared. For a clinical trial, managed access is acceptable, but the statement is not explicit.
“Supplementary Material supp app”
“Associated Data Supplementary Materials”
Trial registration numbers are provided (NCT05492955, SAHPRA, SANCTR). Funding sources are listed. Limitations are discussed in the Discussion. Conclusions are proportional to the evidence. Methods are detailed. Reporting guideline adherence is not explicitly stated but the paper follows CONSORT-like structure.
“Trial Registration: NCT05492955 (https://clinicaltrials.gov/show/NCT05492955) , registered August 5, 2022”
“This IMPACT-BP trial was funded by the US National Institutes of Health (R01 HL144848) and the Wellcome Trust (227167/A/23/Z).”
“Our study is limited by its conduct in two clinics in one region of a single country.”
“Trial Registration: NCT05492955 (https://clinicaltrials.gov/show/NCT05492955) , registered August 5, 2022”
“Our study is limited by its conduct in two clinics in one region of a single country.”
“This IMPACT-BP trial was funded by the US National Institutes of Health (R01 HL144848) and the Wellcome Trust (227167/A/23/Z).”
Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
None found · partly checkedReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.
Checked 25 references by DOI: 1 verified — 24 no DOI (shown, not verified).
- NO DOIGlobal burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGlobal report on hypertension: the race against a silent killerNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe global epidemiology of hypertensionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAddressing global disparities in blood pressure control: perspectives of the International Society of HypertensionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIUnderstanding barriers and facilitators to integrated HIV and hypertension care in South AfricaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA formative evaluation of potential barriers and facilitators to inform effective implementation of a community-based hypertension care program in rural South Africa: The IMPACT-BP trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIResults of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care NetworkNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIProtocol: Implementation Evaluation of a Combination Intervention for Sustainable Blood Pressure Control in Rural KwaZulu-Natal, South Africa (IMPACT BP): A three-arm, unblinded, parallel group individually randomized clinical trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPrimary Healthcare Standard Treatment Guideline and Essential Medicine ListNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEstimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk PredictionsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe REDCap consortium: Building an international community of software platform partnersNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOISouth African hypertension practice guideline 2014No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEQ-SD: a measure of health status from the EuroQol GroupNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIConvergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity studyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEstimating predicted probabilities from logistic regression: different methods correspond to different target populationsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIBlood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICommunity-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe Effectiveness of Telemedicine in Hypertension Management of Adults in Rural Communities: A Systematic Review and Meta-AnalysisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIComparative Effectiveness of Implementation Strategies for Blood Pressure Control in Hypertensive Patients: A Systematic Review and Meta-analysisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA Community-Based Intervention for Managing Hypertension in Rural South AsiaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGroup Medical Visits and Microfinancial Intervention for Patients with Diabetes or Hypertension in KenyaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA Cluster-Randomized Trial of Blood-Pressure Reduction in Black BarbershopsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOISelf-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysisNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe South African National Integrated Men’s Health StrategyNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
Copyediting
6 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 6 minor suggestions below.
6 copyedit issues flagged: mostly consistency, typo, clarity.
- MINORtypoAbstract, Results“CWH (n=257)”→ CHW (n=257)Typo in arm abbreviation.
- MINORconsistencyTable 1, HIV status“133 51.8%)”→ 133 (51.8%)Missing opening parenthesis.
- MINORconsistencyTable 1, Travel time to clinic“41 (33”→ 41 (33)Missing closing parenthesis.
- MINORconsistencyTable 2, Retention in care“76.4% (70.9, 81.2)”→ 76.4% (70.9, 81.2) [n=...]Retention percentages lack denominators.
- MINORclarityMethods, Statistical Analyses“In our primary analysis, those with missing data were censored.”→ In our primary analysis, participants with missing outcome data were excluded (complete-case analysis).Clarify that censoring is not the right term.
- MINORconsistencyResults, paragraph 3“−9.1mmHg, 95%CI −11,1, −6.8”→ −9.1mmHg, 95%CI −11.1, −6.8Comma instead of decimal point.
The published work is robust and generally trustworthy, but an informed reader should weigh the lack of a clear data availability statement and code sharing, and the minor internal inconsistencies (e.g., 76.9% vs 76.8% hypertension control). These do not undermine the main conclusions but warrant clarification or a correction.
- 1.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 89% does not match the reported count 227/259Demonstrable critical failure — blocks the verdict from passing.
- 2.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 89% does not match the reported count 226/257Demonstrable critical failure — blocks the verdict from passing.
- 3.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 87.9% does not match the reported count 225/258Demonstrable critical failure — blocks the verdict from passing.
- 4.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 88.6% does not match the reported count 678/774Demonstrable critical failure — blocks the verdict from passing.
- 5.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 22.7% does not match the reported count 57/257Demonstrable critical failure — blocks the verdict from passing.
- 6.HIGHdata codeAdd an explicit Data Availability statement in the manuscript specifying where de-identified participant data can be accessed (e.g., a repository or managed-access process).The current statement is vague and lacks a repository or access mechanism, which is a transparency gap for a data-driven trial.
- 7.HIGHdata codeProvide the statistical software and version used for analyses (e.g., Stata, R) in the Methods section.The software is not identified, which hinders reproducibility.
- 8.HIGHreportingState adherence to CONSORT guidelines and provide the CONSORT checklist as supplementary material.The paper follows a CONSORT-like structure but does not explicitly reference the guideline, which is expected for a randomized trial.
- 9.MEDIUMreportingClarify the handling of missing outcome data in the Statistical Analyses section (e.g., complete-case analysis vs. censoring).The copyedit flagged that 'censored' is not the correct term for missing outcome data; this needs clarification for accuracy.
- 10.MEDIUMdata codeConsider depositing the analysis code in a public repository (e.g., GitHub) with a DOI.Sharing code enhances reproducibility and is increasingly expected for clinical trials.
- 11.MEDIUMreportingProvide a link to the full trial protocol and statistical analysis plan in the main text or supplementary material.This increases transparency and allows readers to verify pre-specified analyses.
- 12.MEDIUMreportingReconcile the discrepancy in hypertension control rates between the abstract (76.9%) and results (76.8%) for the CHW arm.The integrity check flagged this internal inconsistency, which could confuse readers.
- 13.MEDIUMreportingClarify in the abstract that 762 of 774 randomized participants completed the 6-month follow-up and were included in the primary ITT analysis.The abstract reports 774 randomized but does not mention the 12 missing, which is a minor transparency issue.
- 14.MEDIUMcopyeditFix the typo 'CWH' to 'CHW' in the Abstract, Results section.The copyedit flagged this as a typo in the arm abbreviation.
- 15.MEDIUMcopyeditCorrect the missing parentheses in Table 1 (e.g., '133 51.8%)' to '133 (51.8%)' and '41 (33' to '41 (33)').These are formatting errors that affect readability.
- 16.MEDIUMcopyeditFix the comma instead of decimal point in Results, paragraph 3: '−11,1' to '−11.1'.This is a numerical formatting error that could be misinterpreted.
- 17.LOWreportingAdd denominators to retention percentages in Table 2 (e.g., '76.4% (70.9, 81.2) [n=...]').The copyedit noted that retention percentages lack denominators, which reduces clarity.
- 18.LOWreportingExplicitly describe how outliers were handled in the statistical analysis.Reviewer 2 flagged outlier handling as not explicitly addressed; adding a sentence would improve completeness.
- 19.LOWdata codeSpecify the version of the mobile application and any custom algorithms used for decision support in the Methods.This would improve the description of the intervention and its reproducibility.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.